Total lymphoid irradiation, anti-lymphocyte globulin and Campath 1-G for immunosuppression prior to bone marrow transplantation for aplastic anemia after repeated graft rejection

Bone Marrow Transplant. 1994 Jan;13(1):97-9.

Abstract

Allogeneic BMT for severe aplastic anemia is associated with a significant rate of graft rejection, especially in patients who have been previously transfused. We report a child with aplastic anemia who rejected donor marrow twice despite adequate immunosuppression as part of the conditioning therapy but engrafted successfully following combined administration of three modalities of immunosuppression: antithymocyte globulin, total lymphoid irradiation and the monoclonal antibody Campath-1G. Restriction fragment length polymorphism studies > 1 year after BMT show full donor hematopoiesis with no evidence of autologous recovery.

Publication types

  • Case Reports

MeSH terms

  • Alemtuzumab
  • Anemia, Aplastic / chemically induced
  • Anemia, Aplastic / surgery*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antigens, CD
  • Antigens, Neoplasm*
  • Antilymphocyte Serum / therapeutic use
  • Bone Marrow Transplantation / adverse effects
  • Bone Marrow Transplantation / immunology
  • Bone Marrow Transplantation / methods*
  • CD52 Antigen
  • Child, Preschool
  • Glycoproteins*
  • Graft Rejection
  • Humans
  • Immunosuppression Therapy / methods*
  • Lymphoid Tissue / radiation effects
  • Male
  • Reoperation
  • Tetracycline / adverse effects

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antigens, CD
  • Antigens, Neoplasm
  • Antilymphocyte Serum
  • CD52 Antigen
  • CD52 protein, human
  • Glycoproteins
  • Alemtuzumab
  • Tetracycline